Journal article
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, Arnold Reynaldi, Hannah G Kelly, Kathleen Wragg, Robyn Esterbauer, Helen E Kent, C Jane Batten, Francesca L Mordant, Nicholas A Gherardin, Phillip Pymm, Melanie H Dietrich, Nichollas E Scott, Wai-Hong Tham, Dale Godfrey, Kanta Subbarao, Miles P Davenport, Stephen J Kent, Adam K Wheatley
NATURE MEDICINE | NATURE RESEARCH | Published : 2020
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has dramatically expedited global vaccine development efforts1-3, most targeting the viral 'spike' glycoprotein (S). S localizes on the virion surface and mediates recognition of cellular receptor angiotensin-converting enzyme 2 (ACE2)4-6. Eliciting neutralizing antibodies that block S-ACE2 interaction7-9, or indirectly prevent membrane fusion10, constitute an attractive modality for vaccine-elicited protection11. However, although prototypic S-based vaccines show promise in animal models12-14, the immunogenic properties of S in humans are poorly resolved. In this study, we characterized humoral and circulating follicu..
View full abstractRelated Projects (3)
Grants
Awarded by Medical Research Future Fund (MRFF)
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC
Awarded by Howard Hughes Medical Institute-Wellcome Trust International Research Scholar
Funding Acknowledgements
We thank the generous participation of the trial individuals for providing samples. The SARS-CoV-2 RBD expression plasmids were kindly provided by F. Krammer (Icahn School of Medicine at Mt. Sinai). The human and mouse ACE2 expression plasmids were kindly provided by M. Thomas (Monash University). We acknowledge V. Jameson and staff at the Melbourne Cytometry Platform (Melbourne Brain Centre node) for provision of flow cytometry services. We thank the Melbourne Mass Spectrometry and Proteomics Facility of the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne for the support of mass spectrometry analysis. This study was supported by the Victorian Government and Medical Research Future Fund (MRFF) GNT2002073 (to W.-H.T., D.I.G., M.P.D., S.J.K. and A.K.W.), the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (to S.J.K.), National Health and Medical Research Council (NHMRC) program grant APP1149990 (to S.J.K. and M.P.D.), NHMRC project grant GNT1162760 (to A.K.W), the Jack Ma Foundation (to D.I.G., N.A.G. and K.S.) and the A2 Milk Company (to K.S.). W-H.T. is a Howard Hughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z). J.A.J., D.I.G., M.P.D., W.-H.T., S.J.K. and A.K.W. are supported by NHMRC fellowships. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health.